Stock TLSI TRISALUS LIFE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases TriSalus Life Sciences, Inc.

Equities

TLSI

US89680M1018

End-of-day quote Nasdaq
Other stock markets
 23:00:00 13/06/2024 BST 		5-day change 1st Jan Change
5.77 USD -1.03% Intraday chart for TriSalus Life Sciences, Inc. -4.31% -31.72%
06-03 TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial CI
05-30 Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
BU
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
BU
TriSalus Reports Q1 2024 Financial Results and Business Update
BU
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
BU
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
BU
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
BU
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
BU
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
BU
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
BU
TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
BU
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101
BU
TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors
BU
TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update
BU
TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call
BU
Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications
BU
TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
BU
TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
BU
TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLSI Stock
  4. News TriSalus Life Sciences, Inc.
  5. Press Releases